80 results about "Phytoestrogens" patented technology

This invention provides a novel medical appliance for repairing, regenerating, maintaining, and/or augmenting a bone. The medical appliance generally includes an osteoinductive agent, an osteoinductive enhancer, and a carrier matrix. Also disclosed are methods, compositions, kits, and bone matrix formulations for regenerating, maintaining, and/or augmenting a bone. Exemplary preferred osteoinductive agents include growth factors such as BMP and TGF-β. Exemplary preferred osteoinductive enhancers include phytoestrogens such as naringin.

A composition for the relief and/or prevention of climacteric and menopausal disorders affecting women in pre-, peri- or post-menopause, comprising Soy Isoflavones and viable lactic acid bacteria preferably Lactobacillus sporogenes aimed to enhance the absorption of Soy Isoflavones, the composition being provided in dosage forms for oral administration. Preferably the composition also comprises Equisetum arvense dry extract and a pharmaceutically acceptable calcium salt and/or Vitamin D₃.

A method and kit for enhancing the natural fertility process. The kit includes a vaginal douche that is used prior to intercourse to enhance the sperm transportation and sustaining properties of the cervical mucous. The douche contains a balanced electrolyte solution, polysaccharides, and pH buffers. The kit also includes nutriceuticals specifically formulated for both the male and female which include amino acids, minerals, vitamins, herbs, phytoestrogens, and antioxidants along with a specified dosing regimen. A basal body temperature thermometer and chart is provided with instructions to confirm when and if ovulation will/did occur. Commercially available urinary chemical reagent strips are provided with instructions so as to predict/confirm if and when ovulation will occur. A lubricating medium will also be provided and utilized at the time of intercourse which is nonspermicidal and which contains polysaccharides which influence natural sperm motility. A detailed instruction book regarding the method and practice is provided along with dietary and lifestyle recommendations which have been shown to affect natural fertility.

The present invention provides a method for preventing the adverse effects which may be associated with the administration of at least one hormone to a subject without detectable cancer comprising administering to such subject at least one carotenoid. The invention further provides a method for preventing a variety of adverse effects associated with the administration of hormones, including, for example, an increased risk for developing cancer. The invention further provides a method for preventing adverse effects without inhibiting the beneficial activity of the hormone. The invention further provides a method for preventing the adverse effects associated with administration of estrogen and/or progestin in hormone replacement therapy without inhibiting the beneficial activity of such hormone. The invention further provides a method for preventing the adverse effects associated with the administration of phytoestrogens. The invention further provides a method for preventing adverse effects associated with the administration of phytoestrogens without inhibiting the beneficial activity of such hormone.

A composite vegetative estrin medicine in the form of suppository, gel or film for treating vagititis and improving the toughness of vagina and its resistance to bacteria is proportionally prepared from vegetative estrin, cnidiadin, borneol, and at least one of matrine, phellodendrine, berberine, etc and their physiocologically acceptable salts.

A process for extracting the water-soluble active component of propolis features that it is extracted in water. Said extract can be used for preparing coronary artery dilators and phytoestrogenic medicines.

Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-β, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.

A composite medicine for preventing and treating the retrograde bone lesion, osteoporosis and osteoarthrodynia contains vegetable estrogen (30-50%) and aminoglocose (50-70%), and is prepared through extracting the vegetable estrogen from relative plant, preparing the aminoglocose hydrochloride (or sulfate) from the the shell of shrimp and crab or the chitin, and conventionally preparing said medicine. Its advantages are high curative effect and no toxic by-effect.

The invention provides a preparation method of a soybean sprout powder, wherein the method includes the steps: (1) under germination conditions, making soybean germinated; (2) crushing and pulping the obtained soybean sprouts, at the temperature of 40-45 DEG C, carrying out enzymolysis treatment for 2-3 hours, hydrolyzing soybean isoflavone glycoside contained in the soybean sprouts into soybean isoflavone aglycones; (3) adding a mixed solution of ethanol and ethyl acetate into the pulp obtained in the step (2), centrifuging to obtain an upper solution and soybean sprout dregs; and (4) removing the upper solution, carrying out vacuum drying on the obtained soybean sprout dregs and crushing, and thus obtaining the soybean sprout powder. According to the method provided by the invention, through removing the soybean isoflavone aglycones, gamma-aminobutyric acid with more content can be produced in the soybean sprout powder ultimately, the defect that conventional soybean sprouts and products thereof have the application range (especially application in the infants and children eating field) limited due to containing of soybean isoflavones as phytoestrogen is overcome, and thus the soybean sprout powder becomes a possible in the field of infants and young children foods.

A phytoestrogen blend was developed using a pharmaceutical platform technology to identify the time course of active components and effect time course of these components in the biophase after administration of a red clover extract. This phytoestrogen blend consists of biochanin A, daidzein, equol and genistein. The recommended daily dosage ranges from 5 to 200 mg of total isoflavone.

Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and/or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.

A dietary supplement comprising as its active ingredients soybean, mushroom and mung bean is used in a method to in a method to ameliorate at least one effective malignancy or viral infection or to enhance immune functions. The active components of the dietary supplement include phytoestrogens, β-glucans, saponins, inositol hexaphosphate, and lectins.

The present invention relates to formulations comprising amyris alcohol or an ester of amyris alcohol or combinations thereof to treat acne in humans. These formulations can further comprise a phytoestrogen such as glabridin and miroestrol, an antioxidant such as tetrahydrocurcumin and naturally occurring peroxides such as artemisinin and dihydroartemisinin and combinations thereof for improved effectiveness in treating acne.

Methods and compositions for the prevention and/or treatment of metastatic cancer by tumor encapsulation achieved by introducing a physical obstacle to prevent cancerous cells from escaping the original site and invading other tissues. Physical obstacle is introduced as a pre-formed matter or its assembly by the treated organism is induced. In the preferred embodiment the composition of matter is disclosed, which enables formation of the obstacle in a form of basement membrane (BM). Said composition enables tissue cells to assemble BM on their surfaces, and supplies ECM components for said assembly, whereby BM is assembled de novo or the existing BM is strengthens. The composition comprises soy phytoestrogens, including genistein, daidzein, glycitein, biochantin A, and derivative thereof, actin cytoskeleton reorganization inhibitors, such as Cytochalasin D, and PTK inhibitors, in combination with ECM proteins, such as laminins and type IV collagens, or their derivatives.

The present invention relates to the use, for preventing and/or treating pigmentation disorders, for the preparation of a cosmetic composition suitable for orally administering a dailydose of from 1 to 25 mg of a carotenoid, from 10 to 300 mg of a phytooestrogen and from 10 to 1000 mg of vitamin C.

The invention relates to an application of eriodictyol in preparation of a medicine for treating the AD (alzheimer's disease). A beta 25-35 damaged PC-12 cell is taken as an in-vitro model of the AD,estradiol is taken as positive control, the anti-AD effect of eriodictyol and the action mechanism producing the effect are researched from the view of anti-apoptosis, a solid experimental foundationand theoretical foundation are laid for treatment of the AD and other nervous centralis degenerative diseases by use of phytoestrogen from the molecular level, and the eriodictyol has important actualapplication value.

The prophylactic, therapeutic agent for osteoporosis of the invention is a combination of an indigestible oligosaccharide with phytoestrogen which inhibits bone loss. The action of inhibiting the reduction of bone density can be improved remarkably by combining the indigestible oligosaccharide with phytoestrogen.

The invention relates to a method for screening active components of phytoestrogen. In the method, cotransfection is taken as a base to transfect human breast cancer MCF-7 cells by an expression vector having an exogenous human estrogen receptor gene and a luciferase reporter gene vector having an estrogen response sequence (3*ERE (Estrogen Reaction Element)) according to a ratio; then a phytoestrogen sample to be detected is added to detect the expression of the luciferase and the expression of the luciferase is regulated and controlled by the ERE, thus the active components of the phytoestrogen can be screened. The method has higher specificity and sensibility on screening the active components of the phytoestrogen and can be widely used as a model for screening the active components of the phytoestrogen. The method provided by the invention is simple and flexible, is good in specificity and low in drug dosage, can be used for screening high flux of the active components of the phytoestrogen and effectively solving the problems that the drug dosage is great, the cost is low, the operation is complicated, the result repeatability is poor, the high-flux screening is difficult to satisfy and the like in the traditional method for screening the active components of the phytoestrogen.

The present invention provides compositions comprising optimized ratios of Red clover phytoestrogens as determined by a proprietary physiologically based pharmacokinetic and pharmacodynamic model. The compositions are useful for modulating, preventing or treating postmenopausal or climacteric symptoms, which include but are not limited to bone loss, bone remodeling, hot flushes and vaginal atrophy. The present invention also provides methods for modulating, preventing or treating postmenopausal or climacteric symptoms using the compositions disclosed herein.

A method is disclosed for forming a substantially homogenously colored dehydrated flaked pulse food product which may be simulative of the size, color, texture, and consistency of a dried, crumbled meat product that overcomes several deficiencies associated with textured vegetable protein based simulative meat products. The dehydrated flaked pulse food product is suitable for consumption without requiring further preparation. The method overcomes the requirement that an artificial food coloring be used to achieve a homogenous color, and if pulses other than soy are utilized, the product may be consumable by those with soy allergies and by those who object to the phytoestrogen and hexane content associated with conventional textured vegetable protein based meat analogues. Methods for forming related dehydrated flaked pulse food products are also contemplated which may not necessarily be simulative of any particular meat product.